Walgreens Boots Alliance downgraded by HSBC Securities
$WBA
Retail-Drug Stores and Proprietary Stores
Consumer Staples
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $11.00 → $9.00 | Hold → Sell | Deutsche Bank |
| 2/26/2024 | $23.00 | Market Perform | Leerink Partners |
| 2/20/2024 | Hold → Reduce | HSBC Securities | |
| 1/3/2024 | $21.00 | Underweight | Barclays |
| 12/22/2023 | $27.00 | Hold | HSBC Securities |
| 10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
| 7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
| 6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
15-12G - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
SCHEDULE 13G - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
S-8 POS - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por
Sycamore Partners ("Sycamore") announced today that it has completed its acquisition of Walgreens Boots Alliance, Inc. (the "Company" or "WBA"). Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in WBA, demonstrating their ongoing support and confidence in the Company's future. Stefan Kaluzny, Managing Director of Sycamore, said, "Walgreens Boots Alliance, Inc., its companies and its dedicated team members play an essential role in the communities they serve around the world. We look forward to partnering with the management teams at each company, including Walgreens, The Boots Group, Shields Health Solutio
NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the final results as of 5:00 p.m. (New York City time) on August 27, 2025 (the "Expiration Time"), for the previously announced cash tender offers (each, an "Offer" and, collectively, the "Tender Offer") for any and all of Walgreens Boots Alliance, Inc.'s (NASDAQ:WBA) ("WBA") outstanding (1) 3.600% senior notes due 2025 (the "2025 Notes"), (2) 2.125% senior notes due 2026 (the "2.125% 2026 Notes"), (3) 3.450% notes due 2026 (the "3.450% 2026 Notes"), (4) 8.125% notes due 2029 (the "2029 Notes"), (5) 3.200% notes due 2030 (the "2030 Notes"), (6) 4.500% senior notes due 2034 (the "2034 Notes"),
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal
Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Interactive Brokers Group Inc. (NASD: IBKR) will replace Walgreens Boots Alliance Inc. (NASD: WBA) in the S&P 500, and Talen Energy Corp. (NASD: TLN) will replace Interactive Brokers Group in the S&P MidCap 400 effective prior to the opening of trading on Thursday, August 28. Sycamore Partners is acquiring Walgreens Boots Alliance in a deal expected to be completed soon, pending final closing conditions. Kinetik Holdings Inc. (NYSE:KNTK) will replace Pacific Premier Bancorp Inc. (NASD: PPBI) in the S&P SmallCap 600 ef
Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release
Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th
Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in
Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)